HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $85

Benzinga · 3d ago
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $80 to $85.